SOMATIC GENETIC ALTERATIONS IN GASTROINTESTINAL CANCER

胃肠癌的体细胞遗传改变

基本信息

  • 批准号:
    3176649
  • 负责人:
  • 金额:
    $ 13.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1988
  • 资助国家:
    美国
  • 起止时间:
    1988-09-30 至 1998-02-28
  • 项目状态:
    已结题

项目摘要

We have adapted a DNA fingerprinting approach to detect tumor specific genomic differences. The approach is based in the comparison of the genome fingerprints of normal and tumor tissues from the same individuals, after the amplification of DNA sequences by the Arbitrary Priming Polymerase Chain Reaction (AP-PCR). The method is able to detect in a single and simple experiment, both quantitative and qualitative genomic differences associated with neoplastic transformation. It also allows the cloning in a single step of these altered DNA sequences, including those deleted in the tumor cells. We propose to use this approach as a molecular alternative to the cytogenetic analysis of solid tumors; to estimate the extent and compare the spectrum of genetic alterations occurring in diverse tumors of the digestive tract at different stages of tumor progression; to explore its potential value as prognostic indicator for Cancer of the colon and rectum; and to search for unknown cancer genes in colorectal and other gastrointestinal tumors. We will test the hypothesis that the relative values of genetic damage obtained by the AP-PCR method reflect the degree of aneuploidy of the cancer cells, and that this information might have value for cancer diagnosis and prognosis. The existence of uncharacterized cancer genes involved in the development and/or progression of defined gastrointestinal neoplasms will be searched by isolating and characterizing the chromosomal localization of DNA sequences representing recurrent genetic alterations in these tumors. Genetic alterations will be identified in a panel of about 200 tumors of the gastrointestinal tract including adenomas and carcinomas of the colon and rectum, pancreas and stomach, by comparison of the AP-PCR patterns of tumor versus normal tissues. Genomic alterations specific to the metastatic process of any of these tumors will be searched by comparing primary versus metastatic tumors by the same approach (specific aim 1). We will continue the follow-up of a subset of these tumors (about 100 colorectal carcinomas), which have been already followed for an average of over 3 years for recurrence and survival. These tumors have been already characterized for mutations in the ras oncogene and in the p53 tumor suppressor gene. The relative values of genetic damage obtained for these colorectal carcinomas by the AP-PCR method will be correlated with ras and p53 gene mutations and recurrence and survival rates (specific aim 2). The chromosomal localization of DNA fragments corresponding to recurrent tumor specific genetic alterations will be determined by AP-PCR amplification of panels of human/hamster cell hybrids. When appropriate, these DNA fragments will be cloned and sequenced to further characterize by standard PCR approaches their chromosomal localization and their presence and frequency in other tumors (specific aim 3).
我们已经采用了DNA指纹识别方法来检测肿瘤特异性

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MANUEL PERUCHO其他文献

MANUEL PERUCHO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MANUEL PERUCHO', 18)}}的其他基金

Microsatellite instability and cancer gene expression
微卫星不稳定性与癌症基因表达
  • 批准号:
    6680627
  • 财政年份:
    2003
  • 资助金额:
    $ 13.8万
  • 项目类别:
Microsatellite instability and cancer gene expression
微卫星不稳定性与癌症基因表达
  • 批准号:
    7219945
  • 财政年份:
    2003
  • 资助金额:
    $ 13.8万
  • 项目类别:
Microsatellite instability and cancer gene expression
微卫星不稳定性与癌症基因表达
  • 批准号:
    7077710
  • 财政年份:
    2003
  • 资助金额:
    $ 13.8万
  • 项目类别:
Microsatellite instability and cancer gene expression
微卫星不稳定性与癌症基因表达
  • 批准号:
    6902656
  • 财政年份:
    2003
  • 资助金额:
    $ 13.8万
  • 项目类别:
Microsatellite instability and cancer gene expression
微卫星不稳定性与癌症基因表达
  • 批准号:
    6767682
  • 财政年份:
    2003
  • 资助金额:
    $ 13.8万
  • 项目类别:
MOLECULAR PATHOGENESIS OF CANCER OF MUTATOR PHENOTYPE
突变表型癌症的分子发病机制
  • 批准号:
    2105535
  • 财政年份:
    1994
  • 资助金额:
    $ 13.8万
  • 项目类别:
MOLECULAR PATHOGENESIS OF CANCER OF MUTATOR PHENOTYPE
突变表型癌症的分子发病机制
  • 批准号:
    2852230
  • 财政年份:
    1994
  • 资助金额:
    $ 13.8万
  • 项目类别:
MOLECULAR PATHOGENESIS OF CANCER OF MUTATOR PHENOTYPE
突变表型癌症的分子发病机制
  • 批准号:
    2667978
  • 财政年份:
    1994
  • 资助金额:
    $ 13.8万
  • 项目类别:
MOLECULAR PATHOGENESIS OF CANCER OF MUTATOR PHENOTYPE
突变表型癌症的分子发病机制
  • 批准号:
    2105536
  • 财政年份:
    1994
  • 资助金额:
    $ 13.8万
  • 项目类别:
MOLECULAR PATHOGENESIS OF CANCER OF MUTATOR PHENOTYPE
突变表型癌症的分子发病机制
  • 批准号:
    7235595
  • 财政年份:
    1994
  • 资助金额:
    $ 13.8万
  • 项目类别:

相似国自然基金

大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
  • 批准号:
    30840003
  • 批准年份:
    2008
  • 资助金额:
    12.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
  • 批准号:
    478914
  • 财政年份:
    2023
  • 资助金额:
    $ 13.8万
  • 项目类别:
    Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
  • 批准号:
    23K14913
  • 财政年份:
    2023
  • 资助金额:
    $ 13.8万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
  • 批准号:
    23K15035
  • 财政年份:
    2023
  • 资助金额:
    $ 13.8万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
  • 批准号:
    10442874
  • 财政年份:
    2023
  • 资助金额:
    $ 13.8万
  • 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
  • 批准号:
    10657069
  • 财政年份:
    2023
  • 资助金额:
    $ 13.8万
  • 项目类别:
Control mechanisms of lung adenocarcinoma by SGLT2 inhibitors for treating diabetes mellitus.
SGLT2抑制剂治疗糖尿病对肺腺癌的控制机制。
  • 批准号:
    23K08326
  • 财政年份:
    2023
  • 资助金额:
    $ 13.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of histological transformation model from lung small cell carcinoma from adenocarcinoma to explore the therapeutic strategies of small cell lung carcinoma.
建立肺小细胞癌腺癌组织学转化模型,探讨小细胞肺癌的治疗策略。
  • 批准号:
    23K14614
  • 财政年份:
    2023
  • 资助金额:
    $ 13.8万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms of tumor progression controlled by tumor-initiating cells and cancer-associated fibroblasts in pancreatic adenocarcinoma.
阐明胰腺腺癌中肿瘤起始细胞和癌症相关成纤维细胞控制的肿瘤进展机制。
  • 批准号:
    23K15075
  • 财政年份:
    2023
  • 资助金额:
    $ 13.8万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular mechanisms for development of pulmonary invasive mucinous adenocarcinoma
肺浸润性粘液腺癌发生的分子机制
  • 批准号:
    23H02698
  • 财政年份:
    2023
  • 资助金额:
    $ 13.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Elucidating the Cellular Origins of lung adenocarcinoma
阐明肺腺癌的细胞起源
  • 批准号:
    10743611
  • 财政年份:
    2023
  • 资助金额:
    $ 13.8万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了